Raed Al-Rajabi, MD: STRIDE Regimen Safety in HCC

Dr. Al-Rajabi describes the safety of the STRIDE regimen (durvalumab plus tremelimumab) for patients with hepatocellular carcinoma. He provides an overview of the safety data from the HIMALAYA trial, including immune-related adverse events. Additionally, Dr. Al-Rajabi discusses long-term data on liver function of patients in the HIMALAYA trial.

Topics Covered

Adverse events in patients treated with the STRIDE regimen
Safety data from the HIMALAYA trial
Addressing immune-related adverse events

MORE EXPERT PERSPECTIVES IN GASTOINTESTINAL CANCERS:

R. Katie Kelley, MD: Why Choose Durvalumab + Tremelimumab for the Treatment of uHCC?

Samuel Klempner, MD: The Role of the MATTERHORN Regimen in Resectable GC/GEJC

Dr. Samuel Klempner reviews key data from the MATTERHORN trial, which showed the benefit of perioperative durvalumab plus FLOT in the treatment of resectable gastric cancer/gastroesophageal function cancer. Dr. Klempner highlights EFS and OS gains with the MATTERHORN regimen, and briefly explores its role in clinical practice.

Haley Ellis, MD: Updated Efficacy Data from the TOPAZ-1 Clinical Trial

Learn how durvalumab plus gemcitabine/cisplatin improved long-term survival in the TOPAZ-1 trial, including new four-year overall survival data.

Midhun Malla, MD: Real-World Evidence and Emerging Frontline Therapies for Advanced Hepatocellular Carcinoma

Dr. Midhun Malla discusses the evolving treatment landscape for advanced unresectable hepatocellular carcinoma (HCC), highlighting the positive outcomes of the Phase 3 HIMALAYA trial and the STRIDE regimen of tremelimumab and durvalumab. He emphasizes that real-world evidence increasingly supports these novel immune checkpoint inhibitor combinations, while noting that ongoing trials like Sierra and LIVER-R are essential for evaluating their safety and efficacy in broader, more complex patient populations.

©2026 Oncology Matrix. All Rights Reserved.